Research
Hormonal
Tirzepatide reduced the risk of incident major adverse cardiovascular events (MACEs) compared with liraglutide (hazard ratio, 0.58; 95% confidence interval, 0.51–0.66) and semaglutide (0.86; 0.74–0.99).
Practitioners may consider tirzepatide as a more effective option for reducing cardiovascular risks in patients with OSA and T2D.
StrongSupportsmedium confidence
Tirzepatide reduced the risk of incident MACEs compared with liraglutide (hazard ratio, 0.58; 95% confidence interval, 0.51–0.66) and semaglutide (0.86; 0.74–0.99).
Why this rating
Based on a retrospective cohort analysis in a large global database.
Source
Comparative Efficacy of Tirzepatide, Liraglutide, and Semaglutide in Reduction of Risk of Major Adverse Cardiovascular Events in Patients with Obstructive Sleep Apnea and Type 2 Diabetes: Real-World Evidence
Alex E. Henney et al. · Annals of the American Thoracic Society · 2025
cohort · n=15668Cited 12×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →